{"id":"F2006L02510","name":"National Health Act 1953 - Arrangements made under subparagraph 100(1)(b)(i) - Chemotherapy Pharmaceuticals Access Program (No. PB 37 of 2006)","slug":"f2006l02510","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":324623,"registerId":"commonwealth-F2006L02510-current","compilationNumber":null,"startDate":"2026-04-08","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Commencement","content":"Commencement\n\n1. (a) These Arrangements commence on 1 August 2006.\n\n(b) The Arrangements made on 24 March 2006 with effect from 1 April 2006 (No. PB 20 of 2006) are repealed with effect from the commencement of these Arrangements.\n\n","sortOrder":0},{"sectionNumber":"2","sectionType":"section","heading":"Definitions","content":"Definitions\n\n2. In these Arrangements:\n\n(a) unless the contrary intention appears, a word or phrase will be taken to have the same meaning as in the Act, the Regulations or a declaration, determination or other instrument made under Part VII of the Act or under the Regulations;\n\n(b) “Act” means the National Health Act 1953;\n\n(c) “Medicare Australia CEO” means the Chief Executive Officer of Medicare Australia;\n\n(d) “chemotherapy pharmaceutical” means a special pharmaceutical product in relation to which, by virtue of paragraphs 5, 8 and 12, these Arrangements apply;\n\n(e) “Medicare Australia authority notification computer system” means a computer system operated by the Medicare Australia CEO for the purpose of receiving messages from medical practitioners and sending authorisations for supply of chemotherapy pharmaceuticals or refusals of such authorisations, having an electronic mail address approved by the Medicare Australia CEO;\n\n(f) “hospital” means a public hospital that is participating in the arrangements provided for in Appendix F to Australian Health Care Agreements;\n\n(g) “medical practitioner” means a medical practitioner, within the meaning of the Health Insurance Act 1973, who is affiliated with the hospital in or at which the patient is receiving treatment;\n\n(h) “patient” means a person receiving treatment as a non-admitted patient, a day admitted patient or a patient on discharge of the hospital of which the approved hospital authority is the governing body;\n\n(i) “Regulations” means the National Health (Pharmaceutical Benefits) Regulations 1960 made under the Act.\n\n3. Except where otherwise specified in these Arrangements, the provisions of the Act and the Regulations, and declarations, determinations and other instruments made under the Act shall apply to the prescribing and supply of chemotherapy pharmaceuticals.\n\n","sortOrder":1},{"sectionNumber":"4","sectionType":"section","heading":"Entitlement to receive chemotherapy pharmaceuticals under these Arrangements","content":"Entitlement to receive chemotherapy pharmaceuticals under these Arrangements\n\n4. Subject to these Arrangements, a person who:\n\n(a) is, or is to be treated as, an eligible person within the meaning of the Health Insurance Act 1973; and\n\n(b) is receiving treatment as a non-admitted patient, a day admitted patient or a patient on discharge, of a hospital as defined in paragraph 2(f); and\n\n(c) is receiving medical treatment by a medical practitioner, within the meaning of the Health Insurance Act 1973, who is affiliated with the hospital in or at which the patient is receiving treatment;\n\nis entitled to receive chemotherapy pharmaceuticals under these Arrangements without the payment or furnishing of money or other consideration other than a charge made in accordance with paragraphs 20 and 20A.\n\n5. The special pharmaceutical products to which these Arrangements apply are the chemotherapy pharmaceuticals specified in column 1 of Schedule 1.\n\n6. The prescribing of a chemotherapy pharmaceutical is authorised under these Arrangements only in the circumstances, if any, specified in column 2 of Schedule 1 in relation to the chemotherapy pharmaceutical.\n\n7. The following circumstances are specified in relation to each chemotherapy pharmaceutical:\n\n(a) where a class of persons is specified in column 2 of Schedule 1 — the chemotherapy pharmaceutical is to be supplied for the treatment of a person included in that class of persons; or\n\n \n\n(b) where a disease or condition is specified in column 2 of Schedule 1 —\n\n(i) if subsubparagraph (ii) does not apply — the chemotherapy pharmaceutical is to be supplied for the treatment of that disease or condition in relation to any person; or\n\n(ii) if the disease or condition is specified in relation to a specified class of persons — that the chemotherapy pharmaceutical is to be supplied for the treatment of that disease or condition in a person included in that class of persons; or\n\n(c) where a purpose is specified in column 2 of Schedule 1 — the chemotherapy pharmaceutical is to be supplied for that purpose.\n\n8. Where strength, type of unit, size of unit or other particulars of form are specified in column 2 of Schedule 2 or column 2 of Schedule 3 in relation to a special pharmaceutical product, each specified form of the product is a chemotherapy pharmaceutical, and these Arrangements do not apply in relation to the special pharmaceutical product in any other form.\n\n9. The manner of administration specified in column 3 of Schedule 2 or column 4 of Schedule 3 in relation to a chemotherapy pharmaceutical is the only manner of administration that may be directed to be used in relation to that product.\n\n10. The maximum quantity or number of units of a chemotherapy pharmaceutical that may, in one prescription, be directed to be supplied on any one occasion is:\n\n(a) where the name of the chemotherapy pharmaceutical is specified in column 1 of Schedule 2 — the quantity or number, if any, specified in column 4 of that Schedule in relation to the chemotherapy pharmaceutical; or\n\n(b) where the name of the chemotherapy pharmaceutical is specified in column 1 of Schedule 3 and the chemotherapy pharmaceutical is prescribed in accordance with the provisions of column 3 of that Schedule — the quantity or number, if any, specified in column 5 of that Schedule in relation to the chemotherapy pharmaceutical.\n\n11. The maximum number of occasions, if any, on which the supply of a chemotherapy pharmaceutical may, in one prescription, be directed to be repeated is:\n\n(a) where the name of the chemotherapy pharmaceutical is specified in column 1 of Schedule 2 — the number, if any, specified in column 5 of that Schedule in relation to the chemotherapy pharmaceutical; or\n\n(b) where the name of the chemotherapy pharmaceutical is specified in column 1 of Schedule 3 and the chemotherapy pharmaceutical is prescribed in accordance with the provisions of column 3 of that Schedule — the number, if any, specified in column 6 of that Schedule in relation to the chemotherapy pharmaceutical.\n\n12. The name of the manufacturer or the names of the manufacturers denoted in accordance with the following table by letters specified in column 6 of Schedule 2 or column 7 of Schedule 3 in relation to a special pharmaceutical product is or are the brand or brands under which the special pharmaceutical product may be supplied as a chemotherapy pharmaceutical, and these Arrangements do not apply to the special pharmaceutical product as marketed under any other brand:\n\n

Letters

Manufacturer’s Name

Letters

Manufacturer’s Name

AP

AstraZeneca Pty Ltd

MX

Mayne Pharma Pty Ltd

AV

Aventis Pharma Pty Limited

NV

Novartis Pharmaceuticals Australia Pty Ltd

AW

Arrow Pharmaceuticals Limited

BQ

Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd

OA

Orphan Australia Pty Ltd

OR

Organon (Australia) Pty Limited

PF

Pfizer Pty Limited

BX

Baxter Healthcare Pty Limited

PH

Pharmacia Australia Pty Limited

FB

Pierre Fabre Medicament Australia Pty Limited

PU

Pharmacia & Upjohn Pty Limited

RE

Real-RL Division of GlaxoSmithKline Australia Pty Ltd

GK

GlaxoSmithKline Australia Pty Ltd

HX

Hexal Australia Pty Ltd

RO

Roche Products Pty Ltd

IT

InterPharma Pty Ltd

SE

Servier Laboratories (Aust.) Pty Ltd

JC

Janssen-Cilag Pty Ltd

SH

Schering-Plough Pty Ltd

LY

Eli Lilly Australia Pty Limited

SI

Sigma Pharmaceuticals Pty Ltd

MK

Merck Sharp & Dohme (Australia) Pty Ltd

SW

Sanofi Synthelabo Australia Pty Limited

\n```\n\n","sortOrder":2},{"sectionNumber":"13","sectionType":"section","heading":"Prescribing of chemotherapy pharmaceuticals","content":"Prescribing of chemotherapy pharmaceuticals\n\n13. A medication chart prepared by a medical practitioner, on which is prescribed a chemotherapy pharmaceutical for the medical treatment of a patient of the hospital who is named on the medication chart, will be taken to be a duly written prescription within the meaning of regulation 19 of the Regulations, notwithstanding that it does not comply with the requirements of paragraphs 19(1)(a) and (b) of the Regulations, provided that:\n\n(a) the medication chart bears the number issued by the Medicare Australia CEO, in pursuance of the function granted to him or her by subsection 18(a) of the Medicare Australia (Functions of Chief Executive Officer) Direction 2005 made under paragraph 5(1)(d) of the Medicare Australia Act 1973, to the medical practitioner who prescribed the chemotherapy pharmaceutical; and\n\n(b) if the medication chart contains a direction, pursuant to paragraph 85A(2)(b) of the Act and subparagraph 19(1)(f)(ii) of the Regulations, that the supply of the chemotherapy pharmaceutical is to be repeated, that direction will be invalid; and\n\n(c) if the medication chart contains a direction for the supply of an increased quantity or number of units of the chemotherapy pharmaceutical pursuant to subsection 88(6) of the Act and regulation 24 of the Regulations, that direction will be taken to be a direction to supply the maximum quantity or number of units for that chemotherapy pharmaceutical as specified in Schedule 2 or Schedule 3, as the case may be; and\n\n \n\n(d) if the medication chart contains a direction for the supply of a quantity or number of units of a chemotherapy pharmaceutical greater than the maximum quantity for that chemotherapy pharmaceutical as specified in column 4 of Schedule 2, or column 5 of Schedule 3, as the case may be, an authorisation has been obtained, in accordance with paragraph 15, for the supply of that greater quantity or number of units; and\n\n(e) if the medication chart contains a direction for the supply of a chemotherapy pharmaceutical for which it is necessary to obtain the authorisation of the Medicare Australia CEO pursuant to column 2 of Schedule 1, or column 3 of Schedule 3, an authorisation has been obtained, in accordance with paragraph 14, for the supply of the chemotherapy pharmaceutical.\n\n14. A medical practitioner who wishes to prescribe a chemotherapy pharmaceutical for which an authorisation has to be obtained pursuant to subparagraph 13(e) may:\n\n(a) seek that authorisation in accordance with the provisions of subparagraph 14(d) of the declaration in force under subsection 85(2) of the Act; or\n\n(b) arrange for the authorisation to be sought, on behalf of the medical practitioner, by the approved hospital authority in accordance with paragraph 16.\n\n15. A medical practitioner who wishes to prescribe a quantity of a chemotherapy pharmaceutical for which an authorisation has to be obtained pursuant to subparagraph 13(d) may:\n\n(a) seek that authorisation in accordance with the provisions of regulation 13 of the Regulations; or\n\n(b) arrange for the authorisation to be sought, on behalf of the medical practitioner, by the approved hospital authority in accordance with paragraph 16.\n\n16. Where, pursuant to subparagraph 14(b) or 15(b), a medical practitioner arranges for an approved hospital authority to seek an authorisation for the supply of a chemotherapy pharmaceutical, a pharmacist employed by the approved hospital authority must, on behalf of the medical practitioner, submit details of the medication chart by giving to the Medicare Australia authority notification computer system, by computer message in a manner and form approved by the Medicare Australia CEO, details of the medication chart that has been prepared and signed by the medical practitioner in accordance with regulation 19 of the Regulations, as modified by paragraph 13.\n\n17. Where, on behalf of a medical practitioner, a pharmacist employed by an approved hospital authority submits details of a medication chart to the Medicare Australia authority notification computer system in accordance with paragraph 16, and it is received by that computer system, the computer system may send a message, in a manner and form approved by the Medicare Australia CEO, to the approved hospital authority, and:\n\n(a) if the message indicates that authorisation has been granted, the pharmacist employed by the approved hospital authority must complete the medication chart in accordance with the instructions contained in the message; or\n\n(b) if the message indicates that authorisation has not been granted, or the Medicare Australia authority notification computer system fails to send a message indicating whether or not authorisation has been granted, the medical practitioner may, if the medical practitioner so wishes, resubmit the details of the medication chart to the Medicare Australia CEO in accordance with the provisions of subparagraph 14(d) of the declaration in force under subsection 85(2) of the Act or regulation 13 of the Regulations, as the case may be.\n\n18. When the Medicare Australia authority notification computer system has sent to the approved hospital authority a message indicating that authorisation has been granted, the supply of the chemotherapy pharmaceutical shall be taken to have been approved under these Arrangements.\n\n","sortOrder":3},{"sectionNumber":"19","sectionType":"section","heading":"Supply of chemotherapy pharmaceuticals under these Arrangements","content":"Supply of chemotherapy pharmaceuticals under these Arrangements\n\n19. The approved hospital authority will supply chemotherapy pharmaceuticals to the patients of the hospital as if medication charts were original prescriptions, provided that:\n\n(a) where a medication chart contains a direction to supply more than one chemotherapy pharmaceutical, the approved hospital authority must not, pursuant to regulation 26A of the Regulations, defer the supply of one or more of the chemotherapy pharmaceuticals; and\n\n(b) in lieu of the requirements of regulation 31 of the Regulations, a person authorised for the purpose by the approved hospital authority certifies on the medication chart that the chemotherapy pharmaceutical has been supplied and the date on which it was supplied, and signs his or her name.\n\n","sortOrder":4},{"sectionNumber":"20","sectionType":"section","heading":"Cost to patient of chemotherapy pharmaceuticals supplied under these Arrangements","content":"Cost to patient of chemotherapy pharmaceuticals supplied under these Arrangements\n\n20. An approved hospital authority that supplies a chemotherapy pharmaceutical may charge the person to whom the chemotherapy pharmaceutical is supplied an amount equivalent to the amount that may be charged under subsection 87(2) of the Act for the supply of a pharmaceutical benefit to the person.\n\n20A. In addition to the amount that may be charged by an approved hospital authority under paragraph 20, an approved hospital authority which supplies a chemotherapy pharmaceutical which is:\n\n(i) named in column 1 of Schedule 4;\n\n(ii) in the form specified in column 2 of Schedule 4 in relation to that chemotherapy pharmaceutical;\n\n(iii) marketed under the brand specified in column 3 of Schedule 4 in relation to that chemotherapy pharmaceutical; and\n\n \n\n(iv) in the quantity or number of units specified in column 4 of Schedule 4 in relation to that chemotherapy pharmaceutical;\n\nmay charge the person to whom the chemotherapy pharmaceutical is supplied the amount calculated by subtracting the amount specified in column 5 of Schedule 4 in relation to that chemotherapy pharmaceutical from the amount specified in column 6 of Schedule 4 in relation to that chemotherapy pharmaceutical.\n\n","sortOrder":5},{"sectionNumber":"21","sectionType":"section","heading":"Payment to supplier of chemotherapy pharmaceuticals under these Arrangements","content":"Payment to supplier of chemotherapy pharmaceuticals under these Arrangements\n\n21. An approved hospital authority that has supplied a chemotherapy pharmaceutical is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for the supply of the chemotherapy pharmaceutical exceeds the amount that the approved hospital authority was entitled to charge under paragraph 20.\n\n22. The dispensed price for the supply of a chemotherapy pharmaceutical will be ascertained in accordance with the determination in force under subsection 99(4) of the Act in respect of the supply of pharmaceutical benefits by public hospitals.\n\n23. Regulation 22 and subregulations 25(2), (3) and (4) of the Regulations do not apply to the supply of chemotherapy pharmaceuticals under these Arrangements.\n\n","sortOrder":6},{"sectionNumber":"24","sectionType":"section","heading":"Claims for payment for the supply of chemotherapy pharmaceuticals under these Arrangements","content":"Claims for payment for the supply of chemotherapy pharmaceuticals under these Arrangements\n\n24. The approved hospital authority must prepare an electronic pharmacy record in respect of each medication chart in respect of which a chemotherapy pharmaceutical has been supplied to a patient of the hospital, and must retain that electronic pharmacy record for not less than one year after the day on which the chemotherapy pharmaceutical was supplied.\n\n25. The electronic pharmacy record referred to in paragraph 24 must contain all information required to be included in a prescription record by Part 4 of Schedule 1 to the rules in force under subsection 99AAA(8) of the Act, as modified by paragraph 29 of these Arrangements.\n\n26. Subject to paragraph 27, a claim by the approved hospital authority in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital may be furnished unaccompanied by the medication charts in respect of which chemotherapy pharmaceuticals have been supplied to the patients of the hospital.\n\n27. If the Medicare Australia CEO notifies the approved hospital authority that a copy of all or any of the medication charts in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital is required to be submitted, the approved hospital authority must submit a copy of each such medication chart to the Medicare Australia CEO.\n\n \n\n28. If the Medicare Australia CEO notifies the approved hospital authority that a copy of all or any of the electronic pharmacy records in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital is required to be submitted, the approved hospital authority must submit a copy of each such electronic pharmacy record to the Medicare Australia CEO.\n\n29. Information provided by electronic means to the Secretary by the approved hospital authority in respect of a claim in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital will conform to the requirements of paragraph 5 of, and Schedule 1 to, the rules in force under subsection 99AAA(8) of the Act, provided that Part 4 of Schedule 1 to those rules is amended:\n\n(a) by omitting the specifications for the field “Prescriber Number” and substituting “Seven bytes numeric, right justified, zero filled, being the prescriber number of the prescribing medical practitioner, issued by the Medicare Australia CEO, in pursuance of the function granted to him or her by subsection 18(a) of the Medicare Australia (Functions of Chief Executive Officer) Direction 2005 made under paragraph 5(1)(d) of the Medicare Australia Act 1973”; and\n\n(b) by omitting the field “Filler” and substituting the following field:\n\n“Field: Hospital patient indicator\n\nStart: 32\n\nEnd: 32\n\nSpecifications for field: One byte alphanumeric, value ‘H’ to indicate that the person for whose treatment the medication chart was written was a patient of the hospital; otherwise ‘0’\n\nDated this 26th day of July 2006.\n\nJOAN CORBETT\n\nAssistant Secretary\n\nPharmaceutical Benefits Branch\n\nDepartment of Health and Ageing\n\nDelegate of the Minister for Health and Ageing\n\n

Aprepitant

In compliance with authority procedures set out in paragraph 14:

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, when aprepitant is used in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, where treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy, and where the cytotoxic chemotherapy to be administered to the patient includes any of the following agents:

altretamine;

carmustine;

cisplatin, when a single dose constitutes a cycle of chemotherapy;

cyclophosphamide, at a dose of 1500 mg per square metre per day or greater;

dacarbazine;

procarbazine, when a single dose constitutes a cycle of chemotherapy;

streptozocin

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer where cyclophosphamide and an anthracycline are to be co-administered, when aprepitant is used in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, and where treatment with aprepitant is limited to an intial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy

\"BCG Immunotherapeutic\" (Bacillus Calmette-Guérin/Connaught strain)

Treatment of carcinoma in situ of the urinary bladder

\"BCG-Tice\" (Bacillus Calmette-Guérin/Tice strain)

Primary and relapsing superficial urothelial carcinoma of the bladder

Bleomycin Sulfate

Germ cell neoplasms

Lymphoma

Calcium Folinate

In respect of the tablet equivalent to 15 mg folinic acid:

Antidote to folic acid antagonists

In respect of the injection equivalent to 50 mg folinic acid in 5 mL and injection equivalent to 100 mg folinic acid in 10 mL:

—

Carboplatin

—

Cisplatin

—

Cladribine

In compliance with authority procedures set out in paragraph 14:

Hairy cell leukaemia

Cyclophosphamide

—

Cytarabine

—

Docetaxel

In compliance with authority procedures set out in paragraph 14:

Advanced breast cancer after failure of prior therapy which includes an anthracycline

Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound

Locally advanced or metastatic non-small cell lung cancer

Dolasetron Mesylate

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy

Doxorubicin Hydrochloride

—

Doxorubicin Hydrochloride - Pegylated Liposomal

In compliance with authority procedures set out in paragraph 14:

Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen

Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane

Metastatic breast cancer, as monotherapy, where therapy with capecitabine or a taxane is contraindicated

Epirubicin Hydrochloride

—

Etoposide

—

Etoposide Phosphate

—

Fluorouracil

—

Fotemustine

In compliance with authority procedures set out in paragraph 14:

Metastatic malignant melanoma

Gemcitabine Hydrochloride

In compliance with authority procedures set out in paragraph 14:

Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline

Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy

Locally advanced or metastatic non-small cell lung cancer

Locally advanced or metastatic adenocarcinoma of the pancreas

Locally advanced or metastatic bladder cancer, when used in combination with cisplatin

Granisetron Hydrochloride

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy

Idarubicin Hydrochloride

Acute myelogenous leukaemia

Ifosfamide

Relapsed or refractory germ cell tumours following first-line chemotherapy

Relapsed or refractory sarcomas following first-line chemotherapy

Interferon Alfa-2a

In respect of the injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe:

In compliance with authority procedures set out in paragraph 14:

Hairy cell leukaemia

Myeloproliferative disease with excessive thrombocytosis

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

In respect of the injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe, injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe and injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe:

In compliance with authority procedures set out in paragraph 14:

Myeloproliferative disease with excessive thrombocytosis

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Interferon Alfa-2b

In respect of the solution for injection 18,000,000 I.U. in 1.2 mL multi-dose injection pen:

In compliance with authority procedures set out in paragraph 14:

Hairy cell leukaemia

Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

In respect of the solution for injection 30,000,000 I.U. in 1.2 mL multi-dose injection pen:

In compliance with authority procedures set out in paragraph 14:

Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Irinotecan Hydrochloride Trihydrate

In compliance with authority procedures set out in paragraph 14:

Metastatic colorectal cancer in patients with a World Health Organisation performance status of 2 or less

Mesna

Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide

Methotrexate

—

Mitozantrone Hydrochloride

—

Ondansetron

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy

Ondansetron Hydrochloride Dihydrate

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy

Oxaliplatin

In compliance with authority procedures set out in paragraph 14:

Metastatic colorectal cancer in patients with a World Health Organisation performance status of 2 or less, when used in combination with fluorouracil sodium and calcium folinate

Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with fluorouracil sodium and calcium folinate, following complete resection of the primary tumour

Paclitaxel

In compliance with authority procedures set out in paragraph 14:

Adjuvant treatment of node-positive, oestrogen receptor negative, breast cancer administered sequentially to doxorubicin hydrochloride and cyclophosphamide

Advanced breast cancer after failure of prior therapy which includes an anthracycline

Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound

Primary treatment of ovarian cancer in combination with a platinum compound

Locally advanced or metastatic non-small cell lung cancer

Pemetrexed Disodium Heptahydrate

In compliance with authority procedures set out in paragraph 14:

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with paclitaxel or docetaxel is contraindicated

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where intolerance to treatment with either docetaxel or paclitaxel has developed

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with either docetaxel or paclitaxel has been unsuccessful

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where transfer to docetaxel or paclitaxel is likely to result in adverse clinical consequences

Raltitrexed

In compliance with authority procedures set out in paragraph 14:

For use as a single agent in the treatment of advanced colorectal cancer

Rituximab

In compliance with authority procedures set out in paragraph 14:

Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma

Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma

Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy

Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy

Temozolomide

In respect of the capsule 5 mg, capsule 20 mg and capsule 100 mg:

In compliance with authority procedures set out in paragraph 14:

Glioblastoma multiforme concomitantly with radiotherapy

Recurrence of anaplastic astrocytoma following standard therapy

Recurrence of glioblastoma multiforme following standard therapy

Glioblastoma multiforme following radiotherapy

In respect of the capsule 250 mg:

In compliance with authority procedures set out in paragraph 14:

Recurrence of anaplastic astrocytoma following standard therapy

Recurrence of glioblastoma multiforme following standard therapy

Glioblastoma multiforme following radiotherapy

Thiotepa

—

Topotecan Hydrochloride

In compliance with authority procedures set out in paragraph 14:

Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound

Tropisetron Hydrochloride

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy

Vinblastine Sulfate

—

Vincristine Sulfate

—

Vinorelbine Tartrate

In compliance with authority procedures set out in paragraph 14:

Advanced breast cancer after failure of prior therapy which includes an anthracycline

Locally advanced or metastatic non-small cell lung cancer

\n```\n\n| Aprepitant | Pack containing 1 capsule 125 mg and 2 capsules 80 mg | Oral | 1 | .. | MK |\n| -------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------- | --- | --- | ---------- |\n| \"BCG Immunotherapeutic\" (Bacillus Calmette-Guérin/ Connaught strain) | Single dose set comprising 1 vial powder for intravesical administration containing 6.6 to 19.2 x 108 CFU and 1 vial diluent 3 mL | Intravesical administration | 3 | 1 | AV |\n| \"BCG-Tice\" (Bacillus Calmette-Guérin/Tice strain) | Vial containing powder for intravesical administration approximately 5 x 108 CFU | Intravesical administration | 3 | 1 | OR |\n| Bleomycin Sulfate | Powder for injection 15,000 I.U. | Injection | 10 | .. | BQ, MX, SI |\n| Calcium Folinate | Tablet equivalent to 15 mg folinic acid | Oral | 10 | .. | MX |\n| | Injection equivalent to 50 mg folinic acid in 5 mL | Injection | 5 | 5 | IT, MX, PF |\n| | Injection equivalent to 100 mg folinic acid in 10 mL | Injection | 10 | 1 | IT, PF |\n| Carboplatin | Solution for I.V. injection 50 mg in 5 mL vial | Injection | 2 | .. | MX, PU |\n| | Solution for I.V. injection 150 mg in 15 mL vial | Injection | 6 | .. | MX, PU |\n| | Solution for I.V. injection 450 mg in 45 mL vial | Injection | 2 | .. | MX, PU |\n| Cisplatin | I.V. injection 10 mg in 10 mL | Injection | 1 | .. | PU |\n| | I.V. injection 50 mg in 50 mL | Injection | 1 | .. | MX, PU |\n| | I.V. injection 100 mg in 100 mL | Injection | 1 | .. | IT, MX |\n| Cladribine | Injection 10 mg in 5 mL vial | Injection | 7 | .. | OA |\n| | Solution for I.V. infusion 10 mg in 10 mL single use vial | Injection | 7 | .. | JC |\n| Cyclophosphamide | Powder for injection 500 mg (anhydrous) | Injection | 2 | .. | BX |\n| | Powder for injection 1 g (anhydrous) | Injection | 1 | .. | BX |\n| | Powder for injection 2 g (anhydrous) | Injection | 1 | .. | BX |\n| Cytarabine | Injection 100 mg in 5 mL vial | Injection | 10 | 1 | PU |\n| Docetaxel | Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL | Injection | 2 | .. | AV |\n| | Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL | Injection | 1 | .. | AV |\n| Dolasetron Mesylate | Tablet 200 mg | Oral | 2 | .. | AV |\n| | I.V. injection 100 mg in 5 mL ampoule | Injection | 1 | .. | AV |\n| Doxorubicin Hydrochloride | Solution for I.V. injection or intravesical administration 10 mg in 5 mL single dose vial | Injection or intravesical administration | 4 | .. | IT, MX, PH |\n| | Solution for I.V. injection or intravesical administration 20 mg in 10 mL single dose vial | Injection or intravesical administration | 4 | .. | PH |\n| | Solution for I.V. injection or intravesical administration 50 mg in 25 mL single dose vial | Injection or intravesical administration | 3 | .. | IT, MX, PH |\n| | Solution for I.V. injection or intravesical administration 100 mg in 50 mL single dose vial | Injection or intravesical administration | 1 | .. | IT |\n| | Solution for I.V. injection or intravesical administration 200 mg in 100 mL single dose vial | Injection or intravesical administration | 1 | .. | IT |\n| Doxorubicin Hydrochloride - Pegylated Liposomal | Suspension for I.V. infusion 20 mg in 10 mL vial | Injection | 1 | .. | SH |\n| | Suspension for I.V. infusion 50 mg in 25 mL vial | Injection | 1 | .. | SH |\n| | | | | | |\n\n

Epirubicin Hydrochloride

Solution for injection 10 mg in 5 mL

Injection or intravesical administration

4

..

IT, PH

Solution for injection 20 mg in 10 mL

Injection or intravesical administration

4

..

PH

Solution for injection 50 mg in 25 mL

Injection or intravesical administration

3

..

IT, PH

Powder for injection 50 mg

Injection or intravesical administration

3

..

MX

Solution for injection 100 mg in 50 mL

Injection or intravesical administration

2

..

IT

Solution for injection 200 mg in 100 mL

Injection or intravesical administration

1

..

IT

Etoposide

Solution for I.V. infusion 100 mg in 5 mL vial

Injection

5

..

IT, MX

Etoposide Phosphate

Powder for I.V. infusion 113.6 mg, vial

Injection

5

..

BQ

Powder for I.V. infusion 1.136 g, vial

Injection

1

..

BQ

Fluorouracil

Injection 500 mg in 10 mL

Injection

10

..

IT, MX

Injection 1000 mg in 20 mL

Injection

5

..

IT

Fotemustine

Powder for injection 208 mg with solvent

Injection

1

4

SE

Gemcitabine Hydrochloride

Powder for I.V. infusion equivalent to 200 mg gemcitabine

Injection

4

2

LY

Powder for I.V. infusion equivalent to 1 g gemcitabine

Injection

2

2

LY

Granisetron Hydrochloride

Tablet equivalent to 2 mg granisetron

Oral

2

..

MX

Concentrated injection equivalent to 3 mg granisetron in 3 mL ampoule

Injection

1

..

MX

Idarubicin Hydrochloride

Capsule 5 mg

Oral

3

..

PH

Capsule 10 mg

Oral

3

..

PH

Solution for I.V. injection 5 mg in 5 mL single use vial

Injection

3

..

PH

Solution for I.V. injection 10 mg in 10 mL single use vial

Injection

6

..

PH

Ifosfamide

Powder for I.V. injection 1 g in single dose vial

Injection

5

5

BX

Powder for I.V. injection 2 g in single dose vial

Injection

5

5

BX

Interferon Alfa-2a

Injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

15

4

RO

Injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

5

4

RO

Injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

5

4

RO

Injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

5

4

RO

Interferon Alfa-2b

Solution for injection 18,000,000 I.U. in 1.2 mL multi-dose injection pen

Injection

3

4

SH

Solution for injection 30,000,000 I.U. in 1.2 mL multi-dose injection pen

Injection

3

5

SH

Irinotecan Hydrochloride Trihydrate

I.V. injection 40 mg in 2 mL vial

Injection

1

3

MX, PU

I.V. injection 100 mg in 5 mL vial

Injection

2

3

MX, PU

Mesna

Solution for I.V. injection 400 mg in 4 mL ampoule

Injection

15

5

BX

Solution for I.V. injection 1 g in 10 mL ampoule

Injection

15

5

BX

Methotrexate

Injection 5 mg in 2 mL vial

Injection

5

..

MX

Injection 50 mg in 2 mL vial

Injection

5

..

MX, PU

Solution concentrate for I.V. infusion 500 mg in 5 mL vial

Injection

1

..

IT

Solution concentrate for I.V. infusion 500 mg in 20 mL vial

Injection

1

..

MX

Solution concentrate for I.V. infusion 1000 mg in 10 mL vial

Injection

1

..

IT, MX

Solution concentrate for I.V. infusion 5000 mg in 50 mL vial

Injection

1

..

IT

Mitozantrone Hydrochloride

Injection equivalent to 10 mg mitozantrone in 5 mL vial

Injection

1

..

PU

Injection equivalent to 20 mg mitozantrone in 10 mL vial

Injection

1

..

BX, MX, PU, SI

Injection equivalent to 25 mg mitozantrone in 12.5 mL vial

Injection

1

..

BX, PU, SI

Ondansetron

Wafer 4 mg

Oral

4

..

GK, HX, RE

Wafer 8 mg

Oral

4

..

GK, HX, RE

Ondansetron Hydrochloride Dihydrate

Tablet equivalent to 4 mg ondansetron

Oral

4

..

AW, GK, HX, RE

Tablet equivalent to 8 mg ondansetron

Oral

4

..

AW, GK, HX, RE

I.V. injection equivalent to 4 mg ondansetron in 2 mL ampoule

Injection

1

..

GK, HX, RE

I.V. injection equivalent to 8 mg ondansetron in 4 mL ampoule

Injection

1

..

GK, HX, RE

Oxaliplatin

Solution concentrate for I.V. infusion 50 mg in 10 mL vial

Injection

1

2

SW

Solution concentrate for I.V. infusion 100 mg in 20 mL vial

Injection

1

2

SW

Paclitaxel

Solution concentrate for I.V. infusion 30 mg in 5 mL vial

Injection

5

..

BQ, IT, MX

Solution concentrate for I.V. infusion 100 mg in 16.7 mL vial

Injection

2

..

BQ, IT, MX

Solution concentrate for I.V. infusion 150 mg in 25 mL vial

Injection

2

..

BQ, IT, MX

Solution concentrate for I.V. infusion 300 mg in 50 mL vial

Injection

1

..

BQ, IT, MX

Pemetrexed Disodium Heptahydrate

Powder for I.V. infusion equivalent to 500 mg pemetrexed, vial

Injection

2

2

LY

Raltitrexed

Powder for I.V. infusion 2 mg in single use vial

Injection

3

2

AP

Rituximab

Solution for I.V. infusion 100 mg in 10 mL vial

Injection

2

3

RO

Solution for I.V. infusion 500 mg in 50 mL vial

Injection

1

3

RO

Temozolomide

Capsule 5 mg

Oral

15

2

SH

Capsule 20 mg

Oral

15

2

SH

Capsule 100 mg

Oral

15

2

SH

Capsule 250 mg

Oral

5

5

SH

Thiotepa

Powder for injection 15 mg

Injection or intravesical administration

2

1

SI

Topotecan Hydrochloride

Powder for I.V. infusion equivalent to 4 mg topotecan, vial

Injection

5

1

GK

Tropisetron Hydrochloride

Capsule equivalent to 5 mg tropisetron

Oral

2

..

NV

I.V. injection equivalent to 5 mg tropisetron in 5 mL ampoule

Injection

1

..

NV

Vinblastine Sulfate

Solution for I.V. injection 10 mg in 10 mL vial

Injection

5

..

MX

Vincristine Sulfate

I.V. injection 1 mg in 1 mL vial

Injection

10

..

MX, PU

Vinorelbine Tartrate

Solution for I.V. infusion equivalent to 10 mg vinorelbine in 1 mL vial

Injection

16

2

FB, IT, MX

Solution for I.V. infusion equivalent to 50 mg vinorelbine in 5 mL vial

Injection

4

2

FB, IT, MX

\n```\n\n

Interferon Alfa-2a

Injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe

In compliance with authority procedures set out in paragraph 14:

Injection

15

5

RO

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe

In compliance with authority procedures set out in paragraph 14:

Injection

5

5

RO

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe

In compliance with authority procedures set out in paragraph 14:

Injection

5

5

RO

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe

In compliance with authority procedures set out in paragraph 14:

Injection

5

5

RO

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Interferon Alfa-2b

Solution for injection 18,000,000 I.U. in 1.2 mL multi-dose injection pen

In compliance with authority procedures set out in paragraph 14:

Injection

3

5

SH

Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy

Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy

Pemetrexed Disodium Heptahydrate

Powder for I.V. infusion equivalent to 500 mg pemetrexed, vial

In compliance with authority procedures set out in paragraph 14:

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with paclitaxel or docetaxel is contraindicated

Injection

2

2

LY

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where intolerance to treatment with either docetaxel or paclitaxel has developed

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with either docetaxel or paclitaxel has been unsuccessful

Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where transfer to docetaxel or paclitaxel is likely to result in adverse clinical consequences

\n```\n\n \n\n| Rituximab | Solution for I.V. infusion 100 mg in 10 mL vial | In compliance with authority procedures set out in paragraph 14: | Injection | 2 | 7 | RO |\n| ------------ | ----------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | --------- | --- | --- | --- |\n| | | Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy | | | | |\n| | | Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy | | | | |\n| | Solution for I.V. infusion 500 mg in 50 mL vial | In compliance with authority procedures set out in paragraph 14: | Injection | 1 | 7 | RO |\n| | | Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy | | | | |\n| | | Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy | | | | |\n| Temozolomide | Capsule 5 mg | In compliance with authority procedures set out in paragraph 14: | Oral | 5 | 5 | SH |\n| | | Recurrence of anaplastic astrocytoma following standard therapy | | | | |\n| | | Recurrence of glioblastoma multiforme following standard therapy | | | | |\n| | | Glioblastoma multiforme following radiotherapy | | | | |\n| | Capsule 20 mg | In compliance with authority procedures set out in paragraph 14: | Oral | 5 | 5 | SH |\n| | | Recurrence of anaplastic astrocytoma following standard therapy | | | | |\n| | | Recurrence of glioblastoma multiforme following standard therapy | | | | |\n| | | Glioblastoma multiforme following radiotherapy | | | | |\n| | Capsule 100 mg | In compliance with authority procedures set out in paragraph 14: | Oral | 5 | 5 | SH |\n| | | Recurrence of anaplastic astrocytoma following standard therapy | | | | |\n| | | Recurrence of glioblastoma multiforme following standard therapy | | | | |\n| | | Glioblastoma multiforme following radiotherapy | | | | |\n| | | | | | | |\n\n| Bleomycin Sulfate | Powder for injection 15,000 I.U. | MX | 1 | 44.33 | 84.20 |\n| ----------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---- | --- | ----------- | ----------- |\n| | | SI | 10 | 443.25 | 842.02 |\n| | | BQ | 10 | 443.25 | 910.80 |\n| Calcium Folinate | Injection equivalent to 50 mg folinic acid in 5 mL | MXPF | 110 | 25.59205.31 | 25.60205.51 |\n| | Injection equivalent to 100 mg folinic acid in 10 mL | IT | 1 | 23.62 | 23.63 |\n| Ondansetron | Wafer 4 mg | GK | 4 | 28.38 | 28.95 |\n| | Wafer 8 mg | GK | 4 | 44.45 | 45.03 |\n| Ondansetron Hydrochloride Dihydrate | Tablet equivalent to 4 mg ondansetron | GK | 4 | 28.38 | 28.95 |\n| | Tablet equivalent to 8 mg ondansetron | GK | 4 | 44.45 | 45.03 |\n| | I.V. injection equivalent to 4 mg ondansetron in 2 mL ampoule | GK | 1 | 16.00 | 16.58 |\n| | I.V. injection equivalent to 8 mg ondansetron in 4 mL ampoule | GK | 1 | 25.42 | 25.99 |\n| Pemetrexed DisodiumHeptahydrate | Powder for I.V. infusion equivalent to 500 mg pemetrexed, vial (unless authorisation is obtained in accordance with paragraph 14 for a purpose specified in column 3 of Schedule 3) | LY | 1 | 1395.59 | 1594.95 |\n| | | | | | |","sortOrder":7}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":3317},"content_quality":"ok","complexity_score":7,"scope_assessment":{"changed":false,"description":"This instrument replaces previous arrangements (PB 20 of 2006) to continue the Chemotherapy Pharmaceuticals Access Program. It operates within the established scope of subparagraph 100(1)(b)(i) of the National Health Act 1953, which authorises arrangements for supplying pharmaceutical benefits. The content reflects a routine administrative update specifying eligible drugs, indications, and procedures, without expanding beyond the original purpose of subsidising chemotherapy for hospital outpatients."},"complexity_factors":["Extensive cross-referencing to the National Health Act 1953, National Health (Pharmaceutical Benefits) Regulations 1960, Health Insurance Act 1973, and Medicare Australia Act 1973","Four technical schedules specifying drug names, clinical indications (with authority restrictions), strengths, maximum quantities, repeat limits, approved manufacturers (coded by letters), and pricing","Conditional 'authority' requirements requiring prior electronic approval from the Medicare Australia CEO for specific indications listed in Schedules 1 and 3","Procedural rules treating 'medication charts' as legal prescriptions subject to electronic validation, specific prescriber numbers, and restrictions on repeats","Dual-tier charging structure involving standard co-payments plus additional specific charges for Schedule 4 items calculated by formula"],"plain_english_summary":"This instrument establishes the Chemotherapy Pharmaceuticals Access Program (CPAP), subsidising specified chemotherapy medicines for Medicare‑eligible patients treated as non‑admitted/day or discharge patients in public hospitals. It governs hospital prescribing (medication charts), electronic authority approvals for restricted/high‑cost drugs, pharmacist claims to Services Australia, patient co‑payments, and Commonwealth reimbursement net of patient contributions. It matters because it makes expensive, life‑saving chemotherapy affordable in outpatient settings while maintaining controls on appropriate use."},"flash_summary":{"complexity_score":8,"scope_assessment":{"changed":true,"description":"These Arrangements expressly repeal the prior arrangements made 24 March 2006 (No. PB 20 of 2006) and replace them with an updated schedule of medicines, specified forms, manufacturer/brand limits, authorised indications, electronic authorisation procedures and charging/payment rules (para 1(b); paras 5–16; paras 20–29). The replacement therefore alters the operational scope of which chemotherapy products and processes are covered and how hospitals must authorise, record and claim for supplies."},"complexity_factors":["Extensive, itemised drug schedules with per‑product: indication rules, permitted forms, max quantities, repeat limits and manufacturer/brand constraints (Schedules 1–3; paras 5–12).","Mixed authorisation regimes: some medicines require prior authorisation from Medicare Australia, obtainable by the prescriber or via the hospital authority, adding procedural steps (paras 13–16).","Dependency on a specific electronic authorisation/notification system operated by the Medicare Australia CEO — introduces IT, operational and timing dependencies (paras 13(e), 16–18).","Modifications and exceptions to the standard National Health (Pharmaceutical Benefits) Regulations for this program, changing normal prescription, supply and deferment rules (paras 3,13,19,23).","Cost‑allocation complexity: hospitals may charge patients under paras 20 and 20A while the Commonwealth reimburses the difference based on dispensed price determinations, requiring price reconciliation (paras 20–22).","Record‑keeping and claims obligations require hospitals to create and retain electronic pharmacy records meeting specified data‑field formats and to submit records on request (paras 24–29).","Clinical eligibility criteria and authority procedures embedded in schedule text require case‑by‑case assessment by clinicians and approvers, increasing clinical‑administrative interaction (Schedule 1 col.2; para 14).","Brand/manufacturer restrictions limit which marketed presentations may be supplied under the Arrangements, affecting procurement and supplier selection (para 12; Schedules 2–3 col.6–7).","Transitional/replacement effect: these Arrangements repeal a March 2006 instrument, so hospitals must manage a changeover in covered items and procedures (para 1(b))."],"plain_english_summary":"These Arrangements set the legal rules for prescribing, supplying, charging and paying for a specified list of chemotherapy medicines to eligible public hospital non‑admitted, day‑admitted or discharged patients. They name which drugs and forms are covered, authorised indications, maximum quantities and brand limits; require electronic authorisation for some supplies via a Medicare Australia system; allow hospitals to charge a co‑payment and claim Commonwealth reimbursement for the balance (paras 2,5–13,16–22,24–29)."}},"importantCases":[],"_links":{"self":"/api/acts/f2006l02510","history":"/api/acts/f2006l02510/history","analysis":"/api/acts/f2006l02510/analysis","conflicts":"/api/acts/f2006l02510/conflicts","importantCases":"/api/acts/f2006l02510/important-cases","documents":"/api/acts/f2006l02510/documents"}}